GILDD Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
+ 1 more risk
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.70 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$15.50 |
| Beta | 0.19 |
| 11 Month Change | 2.25% |
| 3 Month Change | 15.23% |
| 1 Year Change | 3.18% |
| 33 Year Change | 23.04% |
| 5 Year Change | n/a |
| Change since IPO | -98.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| GILDD | AR Biotechs | AR Market | |
|---|---|---|---|
| 7D | -1.3% | 0% | 0% |
| 1Y | 3.2% | 0% | 0% |
Return vs Industry: GILDD underperformed the AR Biotechs industry which returned 8.9% over the past year.
Return vs Market: GILDD underperformed the AR Market which returned 134.6% over the past year.
Price Volatility
| GILDD volatility | |
|---|---|
| GILDD Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in AR Market | 0% |
| 10% least volatile stocks in AR Market | 0% |
Stable Share Price: GILDD's share price has been volatile over the past 3 months compared to the AR market.
Volatility Over Time: GILDD's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of AR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GILDD fundamental statistics | |
|---|---|
| Market cap | US$110.46b |
| Earnings (TTM) | US$126.00m |
| Revenue (TTM) | US$28.30b |
887.8x
P/E Ratio4.0x
P/S RatioIs GILDD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILDD income statement (TTM) | |
|---|---|
| Revenue | US$28.30b |
| Cost of Revenue | US$6.28b |
| Gross Profit | US$22.02b |
| Other Expenses | US$21.89b |
| Earnings | US$126.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 77.80% |
| Net Profit Margin | 0.45% |
| Debt/Equity Ratio | 126.4% |
How did GILDD perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield3,027%
Payout RatioDoes GILDD pay a reliable dividends?
See GILDD dividend history and benchmarks| Gilead Sciences dividend dates | |
|---|---|
| Ex Dividend Date | Dec 13 2024 |
| Dividend Pay Date | Dec 30 2024 |
| Days until Ex dividend | 21 days |
| Days until Dividend pay date | 38 days |
Does GILDD pay a reliable dividends?
See GILDD dividend history and benchmarks